Comparative Pharmacology
Head-to-head clinical analysis: ALPHAREDISOL versus HYDROXOCOBALAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAREDISOL versus HYDROXOCOBALAMIN.
ALPHAREDISOL vs HYDROXOCOBALAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyanocobalamin (vitamin B12) acts as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. Alpharedisol is a cyanocobalamin formulation that corrects vitamin B12 deficiency.
Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are essential cofactors for methionine synthase and methylmalonyl-CoA mutase. It facilitates the conversion of homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, and neutralizes cyanide by forming cyanocobalamin.
Hydroxocobalamin 1 mg intramuscularly once daily for 5-10 days, then 1 mg once monthly for life.
1000 mcg intramuscularly once daily for 1 week, then weekly for 1 month, then monthly. For maintenance: 1000 mcg intramuscularly once monthly. Route: IM.
None Documented
None Documented
1.5 hours in healthy adults; prolonged to 3-6 hours in renal impairment
Terminal elimination half-life: ~26-31 days. After high-dose therapy, plasma levels decline more rapidly initially (α-phase half-life ~6 hours) due to distribution, followed by slow terminal elimination reflecting tissue release. Clinically, this supports monthly dosing for deficiency correction.
Renal (90% as unchanged drug); biliary/fecal (10%)
Primarily renal excretion (50-90% as unchanged drug). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement